Johnson & Johnson's (JNJ -0.46%) drug Zytiga was just approved in a pre-chemotherapy indication for late-stage metastatic castration-resistant prostate cancer. This came as no surprise to investors; it received approval in Europe recently for a first-line therapy as well. In the following video, Motley Fool health-care analyst David Williamson talks about why this wasn't a big needle-mover for Johnson & Johnson share prices, but he also tells us that it was a critical step forward not only for J&J, which wants to see Zytiga hit the $1 billion mark, but also for Dendreon (NASDAQ: DNDN), which is working on some tandem treatment trials with Zytiga and its pre-chemo immunotherapy drug Provenge, that could prove to be huge share price drivers if successful.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.